Literature DB >> 17224142

Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc.

Ryo Oikawa1, Yoshihisa Nasa, Rie Ishii, Tomoyuki Kuwaki, Akito Tanoue, Gozoh Tsujimoto, Satoshi Takeo.   

Abstract

The neurohypophyseal peptide [Arg(8)]-vasopressin (AVP) exerts its physiological actions via 3 distinct receptor isoforms designated V1A, V1B, and V2. We recently showed that V1A receptor was involved in the baroreflex control of heart rate using V1A receptor knockout mice. The present study was undertaken to further clarify this finding. In conscious mice, resting blood pressure of the knockout group was lower than that of the wild-type group (wild-type, 108+/-2.0 mm Hg; knockout, 98+/-3.8 mm Hg; n=6-7) without notable change in heart rate. Although phenylephrine and nitroprusside-induced changes in blood pressure did not differ in these strains, the subsequent bradycardia and tachycardia were markedly blunted in the knockout mice (mean slopes for baroreflex curve after phenylephrine treatment; wild-type, -5.65+/-0.30 bpm/mm Hg; knockout, -3.97+/-0.52 bpm/mm Hg; those after nitroprusside treatment; wild-type, -0.51+/-0.10 bpm/mm Hg; knockout, -0.18+/-0.05 bpm/mm Hg; n=6-7). Under urethane anesthesia (1.0-1.2 g/kg, i.p.), electrical stimulation of the vagal afferent nerve evoked frequency-dependent hypotension and bradycardia in the wild-type mice. In contrast, in the knockout mice such stimulation induced a pressor, not a depressor, response and diminished bradycardia. Moreover, electrical stimulation-induced hemodynamic changes through the vagal afferent nerve in the wild-type mice were significantly attenuated by pretreatment with intravenously administered V1A receptor antagonist d(CH(2))(5)Tyr(Me)AVP. Electrical stimulation of the vagal efferent nerve-induced hemodynamic changes (depressor and bradycardia) and chronotropic responses to adrenergic and cholinergic stimuli were not different between the 2 strains. These results suggest that the V1A receptor in the central nervous system is involved in the regulation of the heart rate via the baroreflex arc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17224142     DOI: 10.1016/j.ejphar.2006.11.063

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Vasopressin type 1A receptor deletion enhances cardiac contractility, β-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction.

Authors:  Melissa A Wasilewski; Laurel A Grisanti; Jianliang Song; Rhonda L Carter; Ashley A Repas; Valerie D Myers; Erhe Gao; Walter J Koch; Joseph Y Cheung; Arthur M Feldman; Douglas G Tilley
Journal:  Clin Sci (Lond)       Date:  2016-09-02       Impact factor: 6.124

Review 2.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

3.  Evaluation of the hematoma consequences, neurobehavioral profiles, and histopathology in a rat model of pontine hemorrhage.

Authors:  Tim Lekic; William Rolland; Anatol Manaenko; Paul R Krafft; Joel E Kamper; Hidenori Suzuki; Richard E Hartman; Jiping Tang; John H Zhang
Journal:  J Neurosurg       Date:  2012-11-30       Impact factor: 5.115

4.  Vasopressin and oxytocin in control of the cardiovascular system.

Authors:  Nina Japundžić-Žigon
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 5.  Posterior circulation stroke: animal models and mechanism of disease.

Authors:  Tim Lekic; Chizobam Ani
Journal:  J Biomed Biotechnol       Date:  2012-05-14

6.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

Review 7.  Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.

Authors:  Ewa Szczepanska-Sadowska; Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 8.  Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review.

Authors:  Nina Japundžić-Žigon; Maja Lozić; Olivera Šarenac; David Murphy
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.